Drug Discovery– tag –
-
Beginner-Friendly|What Are Bispecific Antibody Drugs? A Thorough Introduction (Part 1)
Introduction: Why Are Bispecific Antibody Drugs Gaining Attention? In recent years, bispecific antibody drugs (BsAbs) have garnered increasing attention in the treatment of cancer, autoimmune diseases, and infectious diseases. By binding... -
🧬 Unraveling Insulin Resistance and Type 2 Diabetes with Personalized Molecular Maps: The Power of Proteomics and Genomics
Why do some people develop diabetes while others with similar lifestyles don’t?The answer may lie in your molecular fingerprint. This article summarizes groundbreaking findings from a recent Cell (July 2025) paper and integrates insights... -
Pharma/Biotech News | Layoff Trends in the U.S. Biotech Sector 2025: Industry Reset or Prelude to a New Wave?
Fierce Biotech's "Layoff Tracker 2025" has captured a wave of downsizing across the U.S. biotech landscape in the first half of 2025. This article breaks down key layoffs, underlying causes, industry categories impacted, and what this mi... -
Beginner-Friendly in vivo CAR-T Series | Part 8
Global Strategies Shaping the Future of in vivo CAR-T Development Throughout this series, we have explored the cutting-edge developments of in vivo CAR-T therapy in an accessible way for beginners. In this final installment, we will exam... -
Beginner-Friendly in vivo CAR-T Series|Part 7
Key Figures Shaping the Future of in vivo CAR-T This series aims to provide a clear and accessible overview of the latest advancements in in vivo CAR-T therapies, especially for beginners. In Part 7, we focus on the global researchers, e... -
[Beginner-Friendly In vivo CAR-T Series #6] Emerging Technologies Addressing In vivo CAR-T Challenges
In vivo CAR-T therapy has rapidly emerged as a promising next-generation cancer treatment. However, realizing its full potential requires overcoming several hurdles: targeting only the desired cells, ensuring safety, and maintaining sust... -
[Beginner-Friendly In Vivo CAR-T Series #5] Clinical Trial Frontlines and Emerging Biotechs
In previous installments, we've explored the fundamentals of CAR-T, the features of the in vivo model, gene delivery strategies, target antigens, and intracellular signaling. In this fifth edition, we shift our focus to clinical applicat... -
[Introductory In vivo CAR-T Series #4] Deep Dive into CAR Structure: The Latest in Co-stimulation and Signal Engineering
For in vivo CAR-T cells to attack cancer persistently and effectively, the structure of the CAR itself is critical. In particular, the design of co-stimulatory molecules and intracellular signaling domains directly impacts the treatment'... -
[Introductory In vivo CAR-T Series #3] Key to Precision and Safety: Designing Smart CAR Expression
In this third installment of our introductory series on in vivo CAR-T, we focus on a vital component for realizing safe and effective therapy: the design of CAR expression. We explore how “smart control” of CAR expression—targeting tumor... -
【Introductory In vivo CAR-T Series #2】The Technologies Behind In Vivo CAR-T: mRNA, Vectors, and Promoters
In the first installment of our series, we introduced the revolutionary CAR-T cell therapy through the moving story of Emily Whitehead. This time, we take a deep dive into the underlying technologies that make “in vivo CAR-T” possible. F... -
[Introductory In Vivo CAR-T Series #1] The Miracle of Emily: What Is CAR-T Therapy?
CAR-T cell therapy has emerged as a groundbreaking treatment that specifically targets cancer cells. Among its forms, the “in vivo type” CAR-T—where the therapeutic process happens inside the body—is gaining attention as a next-generatio... -
ADC Series – Bonus Chapter: Breakthroughs and the Fierce Global Race for Next-Generation Antibody-Drug Conjugates
Over the past few years, the landscape of Antibody-Drug Conjugates (ADCs) has undergone a dramatic transformation, shifting from a niche therapeutic approach to a central pillar of oncology innovation. This bonus chapter highlights recen... -
ADC Series Part 4: Mechanism of Drug Release and Intracellular Action in Tumor Cells
Antibody-drug conjugates (ADCs) deliver highly potent cytotoxic agents specifically to cancer cells, representing a breakthrough in targeted therapy. This article explains the final stage of ADC function—how the linker system releases th... -
ADC Series Part 3: Antibody Structure and Target Recognition — The Role of the Variable Region
In Antibody-Drug Conjugates (ADCs), antibodies serve as targeting agents that deliver drugs to cancer cells. This article focuses on the "Variable Region," the key structure that enables antibodies to specifically recognize cancer antige... -
Part 2: Basic Structure and Components of ADCs — Understanding the Role of Antibody, Linker, and Payload
Antibody-drug conjugates (ADCs) are next-generation therapeutics gaining attention, especially in oncology. In this second part, we introduce the three fundamental components of ADCs—antibody, linker, and payload—explaining their functio... -
Beginner-Friendly Intro Series
Summer Special|Beginner-Friendly Intro Series Vol.2 (Part 1)What Are Antibodies? The Origin Story of ADCs – A Precision Cancer Weapon Welcome to Part 1 of our Summer Special Beginner Series Vol.2 on Morningglorysciences.This time, we’ll... -
Beginner-Friendly Intro Series
Summer Special|Beginner-Friendly Intro Series Vol.1 (Part 2)Are They Safe? Global Competition and the Future of Anti-Obesity Drugs In Part 1, we explored what anti-obesity medications are, how GLP-1 works, and the key players in the cur... -
Beginner-Friendly Intro Series
Summer Special|Beginner-Friendly Intro Series Vol.1 (Part 1)What Are Slimming Drugs? A Gentle Introduction to Anti-Obesity Medications Welcome to the Morningglorysciences Summer Special Beginner Series!This series is designed for reader... -
Drug Discovery News
BPI Technology Advances Targeted Protein Degradation — A Site-Specific Strategy to Accelerate Drug Discovery Introduction Targeted protein degradation (TPD) has emerged as a transformative strategy in drug discovery, offering a means to ... -
Treatment News
A New Era in Flu Prevention? — CD388 Shows One-Shot Seasonal Protection Introduction Flu prevention has long relied on seasonal vaccines, but a new innovation may challenge that paradigm. CD388, a long-acting antiviral developed by Cidar...